Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Accutane House hearing

Executive Summary

House Energy & Commerce/Oversight Subcommittee is understood to be planning a hearing on a possible link between Roche's Accutane (isotretinoin) and suicide for December. Committee had anticipated holding a hearing this past spring, but refocused its efforts on ImClone (1"The Pink Sheet" Jan. 14, p. 36)...

You may also be interested in...



Accutane safety hearing

House Energy & Commerce/Oversight & Investigations Subcommittee will hold hearing on the possible link between Roche's Accutane and suicide December 11 (1"The Pink Sheet" Oct. 21, In Brief)...

Accutane suicide hearing likely

House Energy & Commerce/Oversight Subcommittee anticipates holding hearing on possible link between Roche's Accutane (isotretinoin) and suicide this spring. Roche has responded to parts of the committee's request for information related to the science behind the acne drug. Charles Bishop, the 15-year old who allegedly committed suicide by crashing an airplane into a Tampa skyscraper, was prescribed Accutane, Tampa police said. Toxicology reports that will determine if Bishop was taking the drug are expected to be complete in about two weeks...

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel